HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
United States225 participantsStarted 2025-01-13
Plain-language summary
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
Who can participate
Age range22 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female subjects aged 22 to 85 years, inclusive
* Subjects presenting with LBP greater than leg pain and symptoms of DDD of the lumbar region (L1- S1) of at least six (6) months duration
* Presence of one (1) or two (2) symptomatic disc(s) (i.e., only 1-level or 2-levels may be treated during the study) as determined by Discography
* Symptomatic disc(s) exhibiting Grade 4 to 8 degeneration on the modified Pfirrmann scale as determined by MRI
* Failure to have their symptoms resolve or reduce following at least six (6) months of conservative care (as defined in the body of the protocol)
* Psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms
* English fluency
* Signed informed consent
Exclusion Criteria:
* History of or active systemic or local infection
* Any skin disease or inadequate tissue coverage at the site of the proposed injection
* Annular tear or defect that shows free contrast extravasation into the epidural space during or after Discography
* Presence of more than two (2) symptomatic discs presenting with pain confirmed during Discography
* Presence of extruded or sequestered disc herniation (i.e., disc extrusions or sequestrations) at the symptomatic level(s) or on adjacent levels
* Presence of wide annular fissures confluent with large disc protrusions at the symptomatic level(s)
* Epidural steroid injection, intra…